MINI FUTURE LONG - NOVO-NORDISK B | Market Closed - Börse Stuttgart 01:33:25 03/05/2024 pm IST | ||
| 19.67 EUR | -4.33% |
|
| Current month | +0.29% | ||
| 1 month | +1.38% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
More news
| Date | Price | Change | Volume |
|---|---|---|---|
| 03/24/03 | 19.67 | -4.33% | 0 |
| 02/24/02 | 20.56 | +0.29% | 0 |
| 30/24/30 | 20.5 | -1.25% | 0 |
| 29/24/29 | 20.76 | +2.01% | 0 |
| 26/24/26 | 20.35 | +0.44% | 0 |
Delayed Quote Börse Stuttgart
Last update May 03, 2024 at 01:33 pm IST
More quotesStatic data
| Product type | Knock-Out with Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | NOVO NORDISK A/S |
| Issuer | 
BNP Paribas
|
| WKN | PR5DL8 |
| ISIN | DE000PR5DL87 |
| Date issued | 28/03/2017 |
| Strike | 111.5 kr |
| Maturity | Unlimited |
| Parity | 5 : 1 |
| Emission price | 0.16 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 21.67 € |
|---|---|
| Lowest since issue | 0.2 € |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
873.1
DKK
Average target price
908.8
DKK
Spread / Average Target
+4.09%
- Stock Market
- Certificates
- Certificat
